BRPI0409551A - derivados de fosfato e método para a fosforilação de um composto que tem um grupo hidróxi secundário - Google Patents

derivados de fosfato e método para a fosforilação de um composto que tem um grupo hidróxi secundário

Info

Publication number
BRPI0409551A
BRPI0409551A BRPI0409551-0A BRPI0409551A BRPI0409551A BR PI0409551 A BRPI0409551 A BR PI0409551A BR PI0409551 A BRPI0409551 A BR PI0409551A BR PI0409551 A BRPI0409551 A BR PI0409551A
Authority
BR
Brazil
Prior art keywords
compound
hydroxy group
phosphorylation
secondary hydroxy
phosphate derivatives
Prior art date
Application number
BRPI0409551-0A
Other languages
English (en)
Inventor
Simon Michael West
David Kannar
Original Assignee
Vital Health Sciences Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vital Health Sciences Pty Ltd filed Critical Vital Health Sciences Pty Ltd
Publication of BRPI0409551A publication Critical patent/BRPI0409551A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/548—Phosphates or phosphonates, e.g. bone-seeking
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/091—Esters of phosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/10—Phosphatides, e.g. lecithin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/117—Esters of phosphoric acids with cycloaliphatic alcohols
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/12—Esters of phosphoric acids with hydroxyaryl compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

"DERIVADOS DE FOSFATO E MéTODO PARA A FOSFORILAçãO DE UM COMPOSTO QUE TEM UM GRUPO HIDRóXI SECUNDáRIO". De acordo com a invenção, é apresentado um derivado de fosfato de um composto que tem um grupo hidróxi secundário. O composto que tem um grupo secundário do hidroxila pode, por exemplo, ser escolhido entre a pravastatina, a atorvastatina venlafaxina, os seus derivados e as misturas destes.
BRPI0409551-0A 2003-04-15 2004-04-14 derivados de fosfato e método para a fosforilação de um composto que tem um grupo hidróxi secundário BRPI0409551A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2003901812A AU2003901812A0 (en) 2003-04-15 2003-04-15 Phosphates of secondary alcohols
PCT/AU2004/000490 WO2004092186A1 (en) 2003-04-15 2004-04-14 Phosphates of secondary alcohols

Publications (1)

Publication Number Publication Date
BRPI0409551A true BRPI0409551A (pt) 2006-04-18

Family

ID=31500849

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0409551-0A BRPI0409551A (pt) 2003-04-15 2004-04-14 derivados de fosfato e método para a fosforilação de um composto que tem um grupo hidróxi secundário

Country Status (10)

Country Link
US (1) US20060281715A1 (pt)
EP (2) EP1615936A4 (pt)
JP (1) JP2006523621A (pt)
KR (1) KR20060006784A (pt)
CN (1) CN100584851C (pt)
AU (1) AU2003901812A0 (pt)
BR (1) BRPI0409551A (pt)
CA (1) CA2521836A1 (pt)
MX (1) MXPA05010510A (pt)
WO (1) WO2004092186A1 (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE444756T1 (de) * 2000-11-14 2009-10-15 Vital Health Sciences Pty Ltd Zusammensetzungen umfassend komplexe von tocopherolphosphatderivaten
AUPR549901A0 (en) * 2001-06-06 2001-07-12 Vital Health Sciences Pty Ltd Topical formulation containing tocopheryl phosphates
WO2003011303A1 (en) * 2001-07-27 2003-02-13 Vital Health Sciences Pty Ltd Dermal therapy using phosphate derivatives of electron transfer agents
CA2466536C (en) * 2001-12-13 2012-02-07 Vital Health Sciences Pty Ltd Transdermal transport of compounds
AU2002950713A0 (en) 2002-08-09 2002-09-12 Vital Health Sciences Pty Ltd Carrier
WO2004064831A1 (en) * 2003-01-17 2004-08-05 Vital Health Sciences Pty Ltd Compounds having anti-proliferative properties
AU2003901815A0 (en) * 2003-04-15 2003-05-01 Vital Health Sciences Pty Ltd Phosphate derivatives
DK1720551T3 (da) 2004-03-03 2011-05-16 Vital Health Sciences Pty Ltd Alkaloidformuleringer
CA2575587C (en) * 2004-08-03 2014-06-17 Vital Health Sciences Pty Ltd Carrier for enteral administration
CA2599424A1 (en) * 2005-03-03 2006-09-08 Vital Health Sciences Pty Ltd Compounds having anti-cancer properties
NZ565049A (en) 2005-06-17 2012-02-24 Vital Health Sciences Pty Ltd A carrier comprising one or more DI and/or mono-(electron transfer agent) phosphate derivatives or complexes thereof
US20090005348A1 (en) * 2005-12-23 2009-01-01 Vital Health Sciences Pty Ltd Compounds Having Cytokine Modulating Properties
ES2999020T3 (en) 2010-02-05 2025-02-24 Phosphagenics Ltd Carrier comprising non-neutralised tocopheryl phosphate
EP2552486B1 (en) 2010-03-30 2020-08-12 Phosphagenics Limited Transdermal delivery patch
WO2012122586A1 (en) 2011-03-15 2012-09-20 Phosphagenics Limited New composition
CN105175263B (zh) * 2015-09-28 2018-06-26 中国食品药品检定研究院 普伐他汀钠药物共晶及其制备方法和用途
CN114712308A (zh) 2015-12-09 2022-07-08 磷肌酸有限公司 药物制剂
EP3558903B1 (en) * 2016-12-21 2024-07-03 Avecho Biotechnology Limited Process for phosphorylating a complex alcohol
FI130262B (en) * 2019-08-30 2023-05-17 Medicortex Finland Oy Formulations and compositions for use in the prevention or treatment of brain injury and neurodegenerative diseases
US12059486B2 (en) 2021-01-13 2024-08-13 Rodan &Fields, LLC Cosmetic compositions

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3331896A (en) * 1964-09-15 1967-07-18 Gen Aniline & Film Corp Method of preparing alkali soluble phosphate esters of hydroxylic organic compounds
US4299906A (en) * 1979-06-01 1981-11-10 American Hoechst Corporation Light-sensitive color proofing film with surfactant in a light-sensitive coating
SU925961A1 (ru) * 1980-08-15 1982-05-07 Московский ордена Трудового Красного Знамени технологический институт пищевой промышленности Способ получени фосфорилированных глицеридов высших жирных кислот
JPS6058084A (ja) * 1983-09-08 1985-04-04 Akira Endo 生理活性物質
JPS61172888A (ja) * 1985-01-29 1986-08-04 Asahi Denka Kogyo Kk 有機リン酸化合物金属塩およびこれを含有する高脂血症治療剤
JPS61249393A (ja) * 1985-04-30 1986-11-06 Asahi Denka Kogyo Kk 菌体固定化物及びその製造法並びにその使用方法
CA2007643A1 (en) * 1989-02-01 1990-08-01 Donald S. Karanewsky Combination of an hmg coa reductase inhibitor and a squalene synthetase inhibitor and method for lowering serum cholesterol using such combination
FI94339C (fi) * 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
WO1992006992A2 (en) * 1990-10-09 1992-04-30 Merck & Co., Inc. New process for biophosphorylating organic compounds
AUPP829399A0 (en) * 1999-01-25 1999-02-18 Swig Pty Ltd Recovery for chroman derivatives
AU766255B2 (en) * 1999-01-25 2003-10-09 Vital Health Sciences Pty Ltd Improved process for phosphorylation and compounds produced by this process
MXPA01011597A (es) * 1999-05-14 2002-06-04 Swig Pty Ltd Proceso mejorado para la fosforilacion y compuestos producidos mediante este proceso.
US6887870B1 (en) * 1999-10-12 2005-05-03 Bristol-Myers Squibb Company Heterocyclic sodium/proton exchange inhibitors and method
WO2001046204A1 (en) * 1999-12-22 2001-06-28 Merck Frosst Canada & Co. Aromatic phosphonates as protein tyrosine phosphatase 1b (ptp-1b) inhibitors
ATE444756T1 (de) * 2000-11-14 2009-10-15 Vital Health Sciences Pty Ltd Zusammensetzungen umfassend komplexe von tocopherolphosphatderivaten
UA76475C2 (en) * 2001-07-19 2006-08-15 Pharmacia Corp Combination of eplerenon and hmg co-a reductase inhibitor and its use for treatment and/or prophylaxis of pathologic condition in cardiovascular system

Also Published As

Publication number Publication date
CN100584851C (zh) 2010-01-27
MXPA05010510A (es) 2005-11-16
EP1615936A4 (en) 2008-04-30
WO2004092186A1 (en) 2004-10-28
EP2085402A1 (en) 2009-08-05
AU2003901812A0 (en) 2003-05-01
JP2006523621A (ja) 2006-10-19
CA2521836A1 (en) 2004-10-28
CN1774443A (zh) 2006-05-17
KR20060006784A (ko) 2006-01-19
US20060281715A1 (en) 2006-12-14
EP1615936A1 (en) 2006-01-18

Similar Documents

Publication Publication Date Title
BRPI0409551A (pt) derivados de fosfato e método para a fosforilação de um composto que tem um grupo hidróxi secundário
BR0010555A (pt) Inibidores de neuraminidases
BR0313723A (pt) Derivados de benzotiazol tendo atividade de agonista beta-2-adrenorreceptor
BR9913288A (pt) Composição antioxidante compreendendo acetil l-carnitina e ácido alfa-lipóico
CL2004000969A1 (es) Compuestos derivados de alquilarilo; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento y/o profilaxis de la obesidad y trastornos relacionados.
BR0206381A (pt) Derivados do ácido fumárico como inibidor de nf-kappab
ES2196377T3 (es) Derivados de naftiridina.
BR9815171A (pt) Composto inibidor de pde iv aplicável no tratamento de doenças, particularmente de asma, em mamìferos e método para tratar um paciente sofrendo estados doentios.
BRPI0312464B8 (pt) compostos inibidores de tirosina quinases, composições farmacêuticas compreendendo os mesmos, processos para fabricação e usos dos mesmos
ECSP045004A (es) Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades andrógeno dependientes
UY26776A1 (es) Inhibidores de 3-hidroxi-3-metilglutaril-coenzima a reductasa y métodos.
AR020345A1 (es) Pirazol-carboxanilidas, procedimiento para su obtencion, composiciones, empleo de dichos compuestos y procedimiento para la lucha contra microorganismos indeseables, y procedimiento para la obtencion de dichas composiciones.
UY26199A1 (es) Nuevos derivados de benceno, un procedimiento para su preparación y las composiciones farmacéuticas que los contienen
BR0112337A (pt) Derivados de fosfolipìdeos de ácido valpróico e suas misturas
BR9813468A (pt) Inibidores triazìnicos da angiogênese
GT199900148A (es) Desnaturalizantes para las sales aminas simpaticomimeticas.
BR0204678A (pt) Inibidor de nf-kb contendo derivado de ácido benzóico substituìdo como ingrediente ativo
BR0212435A (pt) Derivados de 3-(4,5,6,7-tetraidroindol-2-ilmetilideno)-2-indolinona como inibidores de cinase
BR0113389A (pt) Compostos que inibem a atividade do fator xa
BR0008297A (pt) Uso de 4,6-o-(benzilideno-d1) -d-glucopiranose, 4,6-o-benzilideno-l-glucopiranose, e/ou 4,6-o-(benzilideno-d1) -l-glucopiranose, ou um sal farmacêutico aceitável dos mesmos, derivado de benzaldeìdo composição farmacêutica, e, processo para a fabricação da mesma
BR0115306A (pt) Composto, prodroga, composição farmacêutica, agente para diminuir androgênio, método para a produção de um composto, e, sal diastereomérico
BRPI0414822A (pt) método de inibir a produção de lipoproteìna remanescente
AR002017A1 (es) Derivados de fenil-4-tiazoles substituidos, procedimiento para su preparacion, composiciones farmaceuticas que los contienen y derivados defenil-4-tiazoles substituidos empleados en dicho procedimiento.
BRPI0609765A8 (pt) mistura de isoalcano, método para a preparação da mesma, composição cosmética ou farmacêutica, e, uso de uma mistura de isoalcano
ES2134313T3 (es) Utilizacion de derivados de pregnano para el tratamiento de tumores.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2144 DE 07/02/2012.